Literature DB >> 14532144

British Society for Rheumatology Biologics Register.

A Silman1, D Symmons, D G I Scott, I Griffiths.   

Abstract

The British Society for Rheumatology (BSR) established a register of patients newly treated with biological agents, the BSR Biologics Register (BSRBR), which became active in January 2002. The goal is to register all patients in the United Kingdom with rheumatic diseases, newly starting treatment with these agents and to follow them up to determine the incidence of any short and long term hazards to health. The Register is also recruiting a comparison cohort of patients with rheumatoid arthritis treated with standard disease modifying antirheumatic drugs to determine the relative contributions of disease factors and other treatments apart from biological agents on any risks observed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532144      PMCID: PMC1766752          DOI: 10.1136/ard.62.suppl_2.ii28

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  29 in total

Review 1.  Introduction/overview on clinical registries.

Authors:  D D Gladman; A Menter
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 2.  Swedish registers to examine drug safety and clinical issues in RA.

Authors:  J Askling; C M Fored; P Geborek; L T H Jacobsson; R van Vollenhoven; N Feltelius; S Lindblad; L Klareskog
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

Review 3.  Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities.

Authors:  Kazuki Yoshida; Helga Radner; Arthur Kavanaugh; Yoon-Kyoung Sung; Sang-Cheol Bae; Mitsumasa Kishimoto; Kazuo Matsui; Masato Okada; Shigeto Tohma; Michael E Weinblatt; Daniel H Solomon
Journal:  Clin Exp Rheumatol       Date:  2013-10-03       Impact factor: 4.473

4.  Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register.

Authors:  K Hyrich; D Symmons; K Watson; A Silman
Journal:  Ann Rheum Dis       Date:  2005-12-08       Impact factor: 19.103

5.  The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis.

Authors:  M J Harrison; L M Davies; N J Bansback; M J McCoy; S M M Verstappen; K Watson; D P M Symmons
Journal:  Qual Life Res       Date:  2009-09-24       Impact factor: 4.147

6.  Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.

Authors:  Mark J Harrison; Mark Lunt; Suzanne M M Verstappen; Kath D Watson; Nick J Bansback; Deborah P M Symmons
Journal:  Health Qual Life Outcomes       Date:  2010-02-11       Impact factor: 3.186

7.  Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  Suzanne M M Verstappen; Kath D Watson; Mark Lunt; Katie McGrother; Deborah P M Symmons; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2010-05-05       Impact factor: 7.580

8.  Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register.

Authors:  Amr A Saad; Darren M Ashcroft; Kath D Watson; Deborah P M Symmons; Peter R Noyce; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2010-01-07       Impact factor: 7.580

9.  Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database.

Authors:  John Oldroyd; Lionel Schachna; Rachelle Buchbinder; Margaret Staples; Bridie Murphy; Molly Bond; Andrew Briggs; Marissa Lassere; Lyn March
Journal:  Int J Rheumatol       Date:  2009-08-02

10.  Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.

Authors:  Paul A C Lord; Tracey M Farragher; Mark Lunt; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2009-12-23       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.